Thee function of a newly devised bioartificial iiver (AMC-BAL) based on viable, freshly isolatedd porcine hepatocytes has been evaluated in anhepatic pigs. The aim of this study wass to assess the contribution of BAL treatment on blood coagulation parameters.
INTRODUCTION N
Thee liver plays a central role in the regulation of blood coagulation. Hepatocytes synthesizee almost all coagulation factors and coagulation inhibitors as well as components off the fibrinolytic system. In addition, hepatic clearance of activated clotting proteases and protease-proteasee inhibitor complexes importantly modulates coagulation activation. Consequently,, liver failure is always accompanied by a hemostatic defect. Blood coagulationn can be severely compromised especially in patients with fulminant hepatic failuree (FHF), potentially leading to major hemorrhage and possible systemic activation of coagulationn (DIC).
AA bioartificial liver (BAL) is a support system based on viable hepatocytes incorporatedd in an extracorporeal plasma circuit, intended to bridge patients with FHF to transplantationn or liver regeneration. A small number of such hybrid or bioartificial livers iss currently being studied in clinical phase II/III trials (1-3). As liver function is (at least in part)) replaced by a BAL, one might assume that successful treatment with a BAL influencess the hemostatic system in such a way that blood coagulation defects could be moree or less corrected.
AA bioartificial liver (AMC-BAL) has been devised in our institution and is based onn a hollow fiber bioreactor loaded with freshly isolated porcine hepatocytes. The bioreactorr consists of a spirally wound, non-woven polyester matrix to which the hepatocytess attach. In between the layers of the matrix hollow fibers for oxygen transport aree situated for direct oxygenation of the hepatocytes inside the bioreactor. In the AMC-BALL there is a direct contact between plasma of the patient and the hepatocytes, unlike mostt other, membrane-based bioartificial liver systems. It has been shown in vitro that the hepatocytess in the AMC-BAL provide metabolic function(4). Furthermore, it has been demonstratedd that the AMC-BAL prolongs survival in acute liver failure models in rats(5) ass well as in pigs(6;7). In several animal studies, an improvement of the coagulation status duringg treatment with a bioartificial liver has been shown(8-l 1). In these studies, ischemic modelss of fulminant hepatic failure were used in rats and pigs, with or without partial hepatectomy.. It remains unclear whether these better coagulation parameters were due to productionn of coagulation factors in the bioreactor, or due to faster functional recovery of thee remaining (ischemic) liver.
Althoughh the inclusion of a biological component in a liver support system derivess from the assumption that a synthetic function is required next to plasma detoxification,, there is little proof that hepatocytes in a BAL provide vital synthetic products.. The aim of this study was to assess the contribution of the AMC-BAL to blood coagulation,, during treatment of anhepatic pigs.
MATERIALSS AND METHODS

Thee anhepatic model in the pig
Pigss (37-57 kg) were anaesthetized and a total hepatectomy was performed (n=15). The infrahepaticc caval vein and the portal vein were connected to the subdiaphragmatic cava] veinn using a 3-way vascular prosthesis. Postoperatively, all animals were kept under full anesthesiaa and mechanical ventilation until death. No blood transfusions, platelets, fresh frozenn plasma or other substances containing coagulation factors were given during the experiment.. Fetal bovine serum (FBS) is present in the culture medium used to load the hepatocytess in the bioreactor (10% v/v in 450 ml), but this is washed out of the bioreactor beforee connecting the system to the anhepatic pig using 4500 ml of Shiwa (B Braun, Glandorf,, Germany) supplemented with 20 mU/ml Actrapid (Novo Nordisk, Bagsvaerd, Denmark),, 1 M dexamethason-dinatriumphosphate (Centrafarm services B.V., EttenLeur,, The Netherlands), 5% sodium citrate (ACD-Formula A; Emmer Compascum, The Netherlands)) and 20 g/1 human albumin (CLB, Amsterdam, The Netherlands). Body temperaturee was maintained at 38° C using a heating mattress.
Thee BAL-system and experimental groups Autologouss hepatocytes were isolated from the excised liver using a modified isolation procedure (12) .. Calcium free medium (2000 ml) was flushed through the liver via the portall vein followed by recirculating perfusion with Liberase-RH (Roche, Almere, The Netherlands)) solution. After washing the harvested hepatocytes using three centrifuginal (50g)) washing steps, the cells were loaded into the bioreactor. The BAL-system and extracorporeall configuration used in this study have been described previously(4;6;7). Briefly,, the system consists of two pump-driven, parallel circuits. The first circuit, the bloodd circuit, incorporates a centri f ligation plasma-separator (Fresenius AS-104, Fresenius AG,, Bad Homburg, Germany) after which the plasma is pumped through a second circuit includingg the bioreactor. Total cell load of the bioreactor consisted of an average of 10.7 billionn viable hepatocytes (range 7.9 -15.5 billion hepatocytes). Determination of viability wass based on the Trypan blue exclusion test. Sodium citrate (11 g/1, citrate solution versus plasmaa 1:25) was added to the first circuit as anticoagulant. Afterr 24 hours of anhepatic state, the animals were divided into three groups. The first groupp served as absolute control, and received limited intensive care, including mechanicall ventilation and vasopressors, after total hepatectomy (Control, n=5). The secondd group underwent plasma separation and plasma perfusion through a bioreactor withoutt hepatocytes for the next 24 hours (Device Control, n=5). In the third group, plasmaa perfusion took place through a bioreactor loaded with autologous hepatocytes for thee next 24 hours (Cell-loaded BAL-treatment, n=5).
Studyy parameters.
Bloodd and citrated plasma samples were collected preoperatively, and at 4 hourly intervals untill 48 hours after hepatectomy. Platelets were counted by flow cytometry. Antithrombin IIII (AT III) was measured using an amidolytic assay. Prothrombin time (PT), factor II, V, VII,, VIII and fibrinogen were determined using one stage clotting assays with human factorr II, V, VII and VIII deficient plasma and a human fibrinogen standard and Thromborel-SS thromboplastin (Dade Behring, Leusden, The Netherlands). Thrombinantithrombinn III (TAT) complexes, prothrombin fragment Fl+2, tissue-type plasminogen activatorr (t-PA) and plasminogen activator inhibitor type I (PAI-1) were determined using ELISA'ss (Behring, Marburg, Germany). Fl+2, TAT, t-PA and PAI-1 were measured in sampless collected at 0, 8, 20, 24, 28, 32 and 48 hours after hepatectomy.
Statistics s
Resultss are presented as mean standard deviation. Data were analyzed using GraphPad Prismm software (San Diego, CA). Analysis of variance was used to compare the three groups,, and Bonferroni's multiple comparison analysis when overall effects were significantlyy different (p<0.05).
RESULTS S
Anhepaticc model
Noo complications were encountered during the surgical procedure of performing a total hepatectomy.. Total operation time was 145 15 minutes. Blood loss during surgery was 2755 260 ml. These parameters were equally distributed between the three study-groups. Followingg total hepatectomy, all 15 pigs showed rapid stabilization of vital parameters andd continued to have stable hemodynamical and ventilatory parameters for at least 24 hours. .
BAL-treatment t
Thee outcome of the anhepatic animals treated with the BAL has been described elsewhere (7) .. Briefly, survival (mean SD) of the anhepatic pigs was significantly increasedd in the BAL-treated group (65 15 hours), as compared to the control groups (Control:: 46 6 hours and Device Control: 43 14 hours). Mean blood ammonia levels duringg BAL-treatmcnt were significantly lower in the BAL-treated group in comparison too both control groups (p=0.02). All animals showed diffuse, minor bleeding from operationn wounds and introduction sites of intravascular catheters after approximately 24 hourss postoperatively. All animals received moderate intensive care treatment until death. Att autopsy, 100-500 ml of serosanguinolent fluid was found in the abdominal cavity of thee animals. No signs of major bleeding were identified. 
Coagulationn parameters
Meann prothrombin time gradually increased after total hepatectomy, reaching the upper limitt of measurement (40 seconds) after 32 hours in all three groups. Mild thrombocytopeniaa occurred without significant differences between groups (Fig. 1) .
Coagulationn factors II, V and VII. fibrinogen and antithrombin III showed a rapid reductionn after total hepatectomy. without any effect of treatment with the BAL (Fig. 2 ; fibrinogenn data not shown). The decrease of factor VII preceded that of factor II and V. whichh is consistent with the short (6 hours) biological half-life of factor VII. Levels of factorr VIII. the only blood coagulation factor not exclusively produced by the liver, showedd considerable variation between the animals, but overall, was not affected by the anhepaticc state and/or the AMC-BAL treatment (Fig. 3) .
Thrombinn generation, as reflected by prothrombin activation fragment F1+2 and thrombin--antithrombin (TAT) complexes, increased from 1.4 to 135 nmol/1 and from 11 too 344 g/1. respectively, following hepatectomy. After reaching peak values after 20 hours,, these markers rapidly declined but not in the group treated with the AMC-BAL. In thiss group. Fl+2 and TAT levels remained elevated up to the end of the experiment (Fig.  4) ,, indicating de novo synthesis and immediate activation of prothrombin.
Tissue-typee plasminogen activator (t-PA) reached levels one hundred-fold higher thann baseline values and was not affected by BAL or control treatments. Plasma levels of thee fibrinolytic inhibitor. PAI-1, showed a concurrent initial increase from 11 to 64 U/ml att 24 hours after hepatectomy and hereafter rapidly decreased in all groups (Fig. 5 ).
---Control l -*--Device Control ---BAL-treatment Timee after hepatectomy (h) TATT complexes and prothrombin fragment Fl+2 in anhepatic pigs after total hepatectomy (at t = 0 h)) in the three study groups. Data are expressed as means SD. * both control groups versus BALtreatedd P < 0.05; 1 both control groups versus BAL-trcated P < 0.01; § both control groups versus BAL-treatedd P < 0.001.The black bar indicates the 24-hours period in which animals of groups II andd III were connected to the extracorporeal system. DISCUSSION N AA bioartificial liver, serving as a liver-assist device, has a large potential to bridge patients untill a liver graft has become available for transplantation, or to provide liver support allowingg the diseased liver to recover through parenchymal regeneration* 13). In contrast too many other liver support treatments like hemodialysis, hemoperfusion or albumin dialysis,, a bioartificial liver is assumed to replace liver specific synthetic function next to detoxificationn of the plasma. Viable hepatocytes present in a BAL are supposed to replace orr support the patient's multiple and complex own liver functions during liver failure, encompassingg both detoxification and synthesis. Previous studies using the AMC-BAL in ratss and pigs with severe liver failure showed reduced blood ammonia levels, reduced totall bilirubin levels and significantly prolonged survival(5-7). In this study, we tested the hypothesiss that treatment with the biologically active AMC-BAL supports blood coagulationn in a model of acute liver failure. AA total hepatectomy was performed to induce acute hepatic failure in pigs. Synthesiss of procoagulants and coagulation inhibitors are efficiently eliminated in this model,, as well as the capacity of the liver to clear activated coagulation proteins. A situationn of total hepatectomy allows assessment of the pathophysiology of hepatic failure andd the effects of treatment with a BAL, without interference of the release of products of necrosiss of hepatocytes into the systemic circulation. We observed a rapid decline of coagulationn factors produced by the liver. During AMC-BAL treatment, sustained high levelss of TAT complexes and prothrombin fragment F1+2 were seen most likely derived fromm direct activation and complexation of newly synthesized coagulation factors in anhepaticc pigs. These data indicate that BAL treatment indeed results in synthesis of coagulationn proteins. It is less probable that this is due to activation of the coagulation by thee BAL device itself, as the control group and the device control groups show the same results.. However, these newly synthesized factors merely serve as a substrate for the ongoingg activation of coagulation set forth partly by the surgical trauma of hepatectomy andd as a consequence of the induced liver failure. They are not sufficient to restore clottingg factor activity to a measurable amount. How this translates to the clinical setting off fulminant liver failure is a matter of speculation. The synthesis of coagulation proteins possiblyy contributes to improvement of hemostatic function. Alternatively, newly synthesizedd factors may serve to fuel ongoing systemic activation of coagulation, which cann potentially be detrimental. We did however not find any evidence of systemic, macrovascularr thrombus deposition in BAL-treated animals. While both prohemostatic andd antihemostatic mechanisms were affected 24 hours after total hepatectomy, overt diffusee bleeding from operation wounds and skin lesions was seen, along with an increase off PT. A mild thrombocytopenia was apparent in all groups. Worth mentioning is the absencee of splenomegaly or other signs of portal hypertension at autopsy. Although an acute,, acquired platelet dysfunction cannot be excluded, the decrease in platelet count is probablyy clinically insignificant. Coagulation factors II, V, VII and fibrinogen decreased too very low levels, due to the anhepatic state of the animals. Factor VIII levels were not affected,, probably because this clotting protein is not produced exclusively by liver parenchymall cells (14) . The increase and subsequent decrease of plasminogen activity inhibitor-11 is compatible with the activation of the coagulation system in the direct postoperativee period, followed by a depletion of coagulation factors. The rise in t-PA levels,, indicating fibrinolytic activity, has also been observed during the anhepatic phase inn human liver transplantation (15) . Fibrin degradation products (FDP) were not measured, sincee this assay is not only affected by thrombin generation but also by fibrinolytic activity.. Since fibrinolysis is strongly activated in the anhepatic pig (due to very high levelss of plasminogen activator and low levels of plasminogen activator inhibitor), FDP's aree likely to be very high in both situations. Similarly, soluble fibrin levels will increase bothh in case of increased clotting factor synthesis by the BAL and if the BAL itself will activatee coagulation.
Inn conclusion, increased levels of TAT and F1+2 complexes in anhepatic pigs treated with thee AMC-BAL demonstrate release (and most likely synthesis) of coagulation products by thee bioreactor. No effect on other blood coagulation parameters was seen, presumably due too direct consumption of coagulation factors derived from the AMC-BAL during treatmentt of the anhepatic pigs. Timee after hepatectomy (h) 48 8
Figuree 5. t-PAA and PAI-l in anhepatic pigs after total hepatectomy (at t = 0 h) in the three study groups. Data aree expressed as means SD. The black bar indicates the 24-hours period in which animals of groupss II and III were connected to the extracorporeal system.
